Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia. 1998

K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
Department of Traumatology, Osaka University Medical School, Japan. ishikawa@hp-emerg.med.osaka-u.ac.jp

OBJECTIVE The objective of this study was to determine the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration in septic patients with neutropenia. METHODS Twenty consecutive septic patients were administered rhG-CSF subcutaneously (2 microg x kg(-1) x d(-1)) for 5 days (group G). They were compared with 14 septic patients treated earlier without rhG-CSF (group N). All patients in both groups met the criteria of total leukocyte count (TLC) less than 5,000/mm3 and C-reactive protein (CRP) more than 10 mg/dL. Changes in TLC, absolute neutrophil count (ANC), CRP, respiratory index (RI), Acute Physiology and Chronic Health Evaluation (APACHE) II score, and Goris's Multiple Organ Failure (MOF) index were evaluated. In addition, nucleated cell count (NCC), differentiation in bone marrow aspiration, neutrophil phagocytic and bactericidal activity, serum concentrations of interleukin-6 (IL-6) and IL-8 as inflammatory markers, and plasma concentration of leukocyte elastase (LE) as an indicator of the tissue injury were evaluated in group G. RESULTS In group G, TLC, ANC, NCC, and neutrophil functions increased significantly, whereas CRP, IL-6, and IL-8 decreased reciprocally. There was no deterioration of LE and RI. Consequently, the APACHE II score and MOF index improved. In group N, however, CRP showed no change concomitant with the APACHE II score and MOF index. CONCLUSIONS Administration of rhG-CSF attenuates inflammatory responses without inducing tissue injury in septic patients with neutropenia.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009102 Multiple Organ Failure A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative. MODS,Multiple Organ Dysfunction Syndrome,Organ Dysfunction Syndrome, Multiple,Organ Failure, Multiple,Failure, Multiple Organ,Multiple Organ Failures
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
January 1992, Clinical immunology and immunopathology,
K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
February 1998, Annals of hematology,
K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
May 1990, British journal of haematology,
K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
December 1990, AIDS (London, England),
K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
June 1999, Pediatrics,
K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
January 1992, Medical and pediatric oncology,
K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
June 1989, The New England journal of medicine,
K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
January 1991, Haematologica,
K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
January 1993, Klinische Padiatrie,
K Ishikawa, and H Tanaka, and T Matsuoka, and T Shimazu, and T Yoshioka, and H Sugimoto
August 1990, European journal of haematology,
Copied contents to your clipboard!